ICD inducer-2 是一种免疫原性细胞死亡诱导剂,它结合微管蛋白 (tubulin) 上的秋水仙碱结合位点以抑制微管蛋白聚合,在多种癌细胞系中展现出广谱抗增殖活性,可抑制细胞迁移、引发 G2/M 期阻滞并诱导凋亡 (apoptosis),促进 CD4+ 和 CD8+ T 细胞浸润至肿瘤微环境,下调抗凋亡蛋白 Bcl-2,上调促凋亡蛋白 Bax 和 Bim-1,并提高剪切型 caspase 3、剪切型 caspase 9 以及剪切型 PARP 的水平,还能克服异种移植模型中的紫杉醇耐药性、实现肿瘤生长抑制,可用于癌症相关研究,例如肺癌。
产品编号: MS-K83692 CAS No.: 3069681-35-9 分子式: C22H15N3O2S 分子量: 385.44
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

ICD inducer-2 是一种免疫原性细胞死亡诱导剂,它结合微管蛋白 (tubulin) 上的秋水仙碱结合位点以抑制微管蛋白聚合,在多种癌细胞系中展现出广谱抗增殖活性,可抑制细胞迁移、引发 G2/M 期阻滞并诱导凋亡 (apoptosis),促进 CD4+ 和 CD8+ T 细胞浸润至肿瘤微环境,下调抗凋亡蛋白 Bcl-2,上调促凋亡蛋白 Bax 和 Bim-1,并提高剪切型 caspase 3、剪切型 caspase 9 以及剪切型 PARP 的水平,还能克服异种移植模型中的紫杉醇耐药性、实现肿瘤生长抑制,可用于癌症相关研究,例如肺癌。

生物实验数据

生物活性 ICD inducer-2 is an immunogenic cell death inducer that binds to the colchicine-binding site on tubulin to inhibit tubulin polymerization, exhibits broad-spectrum antiproliferative activity across multiple cancer cell lines, inhibits cell migration, induces G2/M phase arrest and apoptosis, promotes CD4+ and CD8+ T cell infiltration into the tumor microenvironment, downregulates the anti-apoptotic protein Bcl-2, upregulates the pro-apoptotic proteins Bax and Bim-1, and increases the levels of cleaved caspase 3, cleaved caspase 9, and cleaved PARP, and can overcome paclitaxel resistance in xenograft models to achieve tumor growth inhibition, making it useful for cancer-related research such as lung cancer.
IC50 & Target

Bcl-2

 

Bax

 

Bim

 

Caspase 9

 

Caspase 3

 

体外研究
(In Vitro)

ICD inducer-2 (Compound 17) (1.25-5 μM; 60 min) 可呈剂量依赖性抑制纯化微管蛋白的聚合。
ICD inducer-2 (0.2-25 μM; 2 h) 可与 A549 细胞中微管蛋白上的秋水仙碱结合位点结合。
ICD inducer-2 (10-20 nM; 48 h) 可在 10 nM 和 20 nM 浓度下破坏 A549 细胞中的微管网络。
ICD inducer-2 (20-80 nM; 12 h) 可在 20、40 和 80 nM 浓度下强效诱导 A549 细胞发生免疫原性细胞死亡 (ICD)。
ICD inducer-2 (8-64 nM; 12-24 h) 具有体外免疫刺激潜力,在与 Jurkat 细胞共培养的体系中,可降低 A549 细胞的存活率。
ICD inducer-2 (48 h) 对多种癌细胞系具有广谱抗增殖活性,其 IC50 值范围为 8 ± 3 nM (MCF-7) 至 47 ± 12 nM (A549/TxR),并可逆转 A549/TxR 细胞的紫杉醇耐药性,RI 为 4.7。
ICD inducer-2 (5-20 nM; 48 h) 可诱导 A549 细胞发生剂量依赖性 G2/M 期阻滞,对应的阻滞率分别为 20.16%、32.83% 和 40.30%,并可调控细胞周期调控蛋白。
ICD inducer-2 (5-20 nM; 48 h) 可诱导 A549 细胞发生剂量依赖性的线粒体介导的细胞凋亡,增加晚期凋亡水平并调控凋亡相关蛋白的表达。
ICD inducer-2 (5-20 nM; 24 h) 可以剂量依赖的方式抑制 A549 细胞迁移。
ICD inducer-2 (5-20 nM; 8 h) 可剂量依赖性抑制 HUVEC 管形成。

Western Blot Analysis

Cell Line: A549 cells
Concentration: 0.2, 1, 5, 25 μM
Incubation Time: 2 h
Result: Effectively suppressed the formation of the EBI/β-tubulin complex band, confirming binding to the colchicine-binding site on tubulin.

Immunofluorescence

Cell Line: A549 cells
Concentration: 10, 20 nM
Incubation Time: 48 h
Result: Induced obvious microtubule network depolymerization, characterized by disorganized structures and diminished fluorescence signal.
Induced more severe disruption than colchicine at 20 nM.

Cell Viability Assay

Cell Line: A549 cells, Jurkat cells
Concentration: 8, 16, 32, 64 nM
Incubation Time: 12-24 h
Result: Significantly reduced the viability of A549 cells in the co-culture group compared to the A549 monoculture group in a dose-dependent manner, indicating immunostimulatory potential.

Cell Cycle Analysis

Cell Line: A549 cells
Concentration: 5, 10, 20 nM
Incubation Time: 48 h
Result: Induced G2/M phase arrest with blocking rates of 20.16% (5 nM), 32.83% (10 nM), and 40.30% (20 nM) in a dose-dependent manner.
Regulated the expression of cell cycle proteins Cdc25c, CDK7, cyclin B1, and P21.

Apoptosis Analysis

Cell Line: A549 cells
Concentration: 5, 10, 20 nM
Incubation Time: 48 h
Result: Significantly increased late-stage apoptosis in a dose-dependent manner.
Downregulated antiapoptotic protein Bcl-2, upregulated proapoptotic proteins Bax and Bim-1, and increased cleaved caspase 3, cleaved caspase 9, and cleaved PARP levels.
体内研究
(In Vivo)

ICD inducer-2 (Compound 17) (5-15 mg/kg;静脉注射;每两天一次;28 天) 在紫杉醇耐药的 A549/TxR 异种移植小鼠模型中实现了剂量依赖性的肿瘤生长抑制,最高抑制率可达 82.0%,且在测试的最大剂量下未观察到明显的主要器官毒性。
ICD inducer-2 (10-15 mg/kg;静脉注射;每两天一次;14 天) 在 Lewis 肺癌异种移植小鼠模型中实现了最高达 81.6%的剂量依赖性肿瘤生长抑制,同时可通过增加 T 细胞浸润和促炎细胞因子产生有效激活抗肿瘤免疫反应,且在测试剂量下具有良好的安全性特征。

Animal Model: BALB/c-nu nude mice with A549/TxR xenograft (male)
Dosage: 5 mg/kg; 10 mg/kg; 15 mg/kg
Administration: i.v.; once every two days; 28 days
Result: Achieved tumor growth inhibition rates of 67.3%, 77.1%, and 82.0% at doses of 5, 10, and 15 mg/kg, respectively.
Showed a tumor growth inhibition rate of 77.1% at 10 mg/kg, which was markedly greater than that of the same dose of Paclitaxel (HY-B0015) (17.6%).
Revealed no evident toxicity in major organs at the maximal dose of 15 mg/kg.
Animal Model: C57BL/6N mice with Lewis lung carcinoma xenograft
Dosage: 10 mg/kg; 15 mg/kg
Administration: i.v.; once every two days; 14 days
Result: Achieved tumor growth inhibition rates of 72.4% at 10 mg/kg and 81.6% at 15 mg/kg.
Showed a tumor growth inhibition rate of 72.4% at 10 mg/kg, which surpassed that of the same dose of paclitaxel (64.2%).
Increased the proportions of CD4+ and CD8+ T cells in tumor tissue to 7.008% and 7.439% at 10 mg/kg, respectively, significantly higher than the blank control group (3.334% and 3.658%) and slightly greater than the Paclitaxel group (6.627% and 6.559%).
Increased the proportions of CD4+ and CD8+ T cells in tumor tissue to 9.239% and 8.604% at 15 mg/kg, respectively.
Significantly increased serum levels of IFN-γ, IL-2, and IL-12, with higher levels than paclitaxel at the 10 mg/kg dose.
Induced marked calreticulin exposure and HMGB1 release in tumor cells, with greater effects than paclitaxel at the 10 mg/kg dose.
Showed no significant changes in body weight and no obvious toxicity in major organ tissues at 15 mg/kg.

化学信息

分子量 385.44
分子式 C22H15N3O2S
CAS No. 3069681-35-9

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础